1. HIV and Non-communicable Diseases Pre-Conference, July 15-16, 2011, Rome Gaps in Knowledge, and Future Research Priorities in LMIC NCD Risk in PLWH 1.What is the level of risk of NCD (such as elevated blood pressure, dyslipidemia, cardiomyopathy and disordered glucose metabolism) in PLWH in LMIC as a result: a)NCD risk factors such as smoking b)HIV disease c)HAART 2.Is there a difference in NCD complications in PLWH in children, and between men and women? e.g. high cardiac mortality in children with maternally- acquired HIV. 3.Is the NCD risk in PLWH high enough to warrant routine monitoring in HIV care and treatment programs? 4.What is the clinical significance of impaired glucose tolerance in the patients with HIV? Should it be treated, and how?

2. HIV and Non-communicable Diseases Pre-Conference, July 15-16, 2011, Rome Gaps in Knowledge, and Future Research Priorities in LMIC NCD Risk and HAART 1.Should HAART protocol be modified in PLWH with NCD risk factors in LMIC? e.g. AZT and Stavudine may affect myocardial function. 2.Are NCD risks higher in LMIC as a result of intermittent HAART therapy because of poor adherence (intermittent therapy has been shown to increase CVD risk - RCT) Monitoring of NCD Risk in PLWH 1.What are the recommended metabolic and anthropometric monitoring recommended for PLWH on care and PLWH on HAART e.g. blood lipids, blood glucose, blood pressure, BMI, visceral fat gain, loss of subcutaneous fat

3. HIV and Non-communicable Diseases Pre-Conference, July 15-16, 2011, Rome Gaps in Knowledge, and Future Research Priorities in LMIC NCD and HAART Drug Interactions 1.What are the possible drug interactions of NCD therapy with HAART – e.g. lipid-lowering drugs, anti-hypertensive agents, etc.? NCD/HIV Integration research 1.What is the appropriate integration target population? a)Use HIV platform to integrate for general population b)Use HIV platform to integrate for all PLWH c)Use HIV platform to integrate for only PLWH at risk of NCD 2.What are the most feasible cost-effective integration models without reducing the effectiveness of the component HIV and NCD programs?